Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Arvinas, Inc. (NASDAQ:ARVN) has earned a consensus recommendation of “Moderate Buy” from the sixteen brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $61.13.

A number of research analysts have recently commented on ARVN shares. Barclays increased their target price on shares of Arvinas from $26.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. HC Wainwright restated a “buy” rating and issued a $87.00 target price on shares of Arvinas in a research report on Friday, May 17th. Stifel Nicolaus lowered their price target on shares of Arvinas from $72.00 to $68.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. BMO Capital Markets increased their price target on Arvinas from $89.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Finally, Wedbush restated an “outperform” rating and set a $57.00 price objective on shares of Arvinas in a research report on Wednesday, May 8th.

Hedge Funds Weigh In On Arvinas

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Corton Capital Inc. increased its position in Arvinas by 132.9% during the 3rd quarter. Corton Capital Inc. now owns 21,750 shares of the company’s stock valued at $427,000 after purchasing an additional 12,411 shares during the period. Great Point Partners LLC bought a new position in Arvinas during the fourth quarter worth $9,635,000. Charles Schwab Investment Management Inc. raised its stake in Arvinas by 9.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 469,474 shares of the company’s stock worth $19,324,000 after buying an additional 39,484 shares during the last quarter. Rhenman & Partners Asset Management AB boosted its position in Arvinas by 58.0% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 134,270 shares of the company’s stock valued at $5,527,000 after acquiring an additional 49,270 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. bought a new stake in Arvinas during the fourth quarter valued at $2,506,000. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Trading Down 2.9 %

Shares of Arvinas stock opened at $25.67 on Monday. The company has a market cap of $1.76 billion, a PE ratio of -4.33 and a beta of 1.98. The company has a 50 day moving average of $32.42 and a 200-day moving average of $37.91. Arvinas has a 1-year low of $13.57 and a 1-year high of $53.08.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.45. The company had revenue of $25.30 million for the quarter, compared to analyst estimates of $32.94 million. Arvinas had a negative return on equity of 64.79% and a negative net margin of 185.09%. The company’s revenue for the quarter was down 22.2% compared to the same quarter last year. During the same quarter last year, the company posted ($1.54) EPS. Research analysts forecast that Arvinas will post -4.08 earnings per share for the current year.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.